DGAP-News: iovera Wins Good Design Award

        Print
| Source: EQS Group AG
DGAP-News: myoscience /
iovera Wins Good Design Award

07.01.2014 / 15:00

---------------------------------------------------------------------

REDWOOD CITY, Calif., 2014-01-07 15:00 CET (GLOBE NEWSWIRE) --
Myoscience is pleased to announce that the iovera*(r) system has won in the
medical category of the GOOD DESIGN(TM) competition. GOOD DESIGN recognizes the
world's most important consumer design products and is one of the most
prestigious and oldest design awards. The awards are organized annually by The
Chicago Athenaeum Museum of Architecture and Design in cooperation with the
European Centre for Architecture, Art, Design and Urban Studies. 

Over 700 new products and graphic designs were selected from more than 38
countries for categories including electronics, robotics, children's products
and transportation. The winning entries were awarded for innovation in a
variety of areas such as sustainability, creativity, human impact, technology
and universal design. 

The iovera* system, developed by myoscience, inc. harnesses the power of cold
using Focused Cold Therapy(TM), the advanced technology that powers the device.
The iovera* treatment works immediately for both health and beauty applications
without leaving any toxins or chemicals behind in the body. The iovera* system
is approved in the European Union and Canada for the treatment of wrinkles, and
is FDA cleared for the treatment of pain in the United States. 

'The iovera* system was designed to change the way that physicians address the
temporary treatment for pain and wrinkles,' says myoscience CEO Clint Carnell.
'The Focused Cold Therapy technology enables physicians to treat using only the
power of cold delivered with a simple and intuitive one-button device. The
engineers and designers at LUNAR worked hard in collaboration with the
myoscience team to ensure we created a beautiful and effective product.' This
is the second design award for the iovera* system, following on the heels of
the Spark! Design award, where the iovera* system received the highest honors
in the general consumer design category. 

To see the full list of awards:

http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_MASTER-list.pdf

To see the press release from GOOD DESIGN:

http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_PRESS_INFO.pdf

ABOUT THE GOOD DESIGN(TM) AWARD

GOOD DESIGN(tm) is the world's most prestigious, recognized, and oldest Design
Awards program organized annually by The Chicago Athenaeum Museum of
Architecture and Design in cooperation with the European Centre for
Architecture, Art, Design and Urban Studies. GOOD DESIGN covers new consumer
products designed and manufactured in Europe, Asia, Africa, and North and South
America. http://www.chi-athenaeum.org/gdesign/index.html 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is the technology underlying the iovera* treatment, which is
currently approved in Europe and Canada for temporary wrinkle reduction,
temporary pain reduction and treatment of dermatologic conditions. The iovera*
system has also been cleared in the United States for use in pain management
and general surgical use. For more information, please visit
www.myoscience.com. 

(c) 2013 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience. 


         CONTACT: MEDIA RELATIONS
         Johanna Beckmen / mediarelations@myoscience.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

07.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     myoscience     
 
 
             United States  
ISIN:        US9902131674   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
247130 07.01.2014